<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRALIDOXIME CHLORIDE</span><br/>(pra-li-dox'eem)<br/><span class="topboxtradename">2-PAM, </span><span class="topboxtradename">Protopam Chloride<br/></span><b>Classifications:</b> <span class="classification">antidote</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>600 mg, 1 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Reactivates cholinesterase inhibited by phosphate esters by displacing the enzyme from its receptor sites; the free enzyme
         then can resume its function of degrading accumulated acetylcholine, thereby restoring normal neuromuscular transmission.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Less effective against carbamate anticholinesterases (ambenonium, neostigmine, pyridostigmine). More active against effects
         of anticholinesterases at skeletal neuromuscular junction than at autonomic effector sites or in CNS respiratory center; therefore,
         atropine must be given concomitantly to block effects of acetylcholine and its accumulation in these sites.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>As antidote in treatment of poisoning by organophosphate insecticides and pesticides with anticholinesterase activity (e.g.,
         parathion, TEPP, sarin) and to control overdosage by anticholinesterase drugs used in treatment of myasthenia gravis (cholinergic
         crisis).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To reverse toxicity of echothiophate ophthalmic solution.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use in poisoning by carbamate insecticide Sevin, inorganic phosphates, or organophosphates having no anticholinesterase activity;
         asthma, peptic ulcer, severe cardiac disease, patients receiving aminophylline, theophylline, morphine, succinylcholine, reserpine,
         or phenothiazines; pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myasthenia gravis; renal insufficiency; concomitant use of barbiturates in organophosphorous poisoning; lactation, children.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Organophosphate Poisoning</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 g in 100 mL NS infused over 1530 min; or 12 g as 5% solution in sterile water over not less than
               5 min, may repeat after 1 h if muscle weakness not relieved <span class="rdroute">IM/SC</span> 12 g if IV route is not feasible<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 2040 mg/kg. May repeat in 12 h if needed.<br/><br/><span class="indicationtitle">Anticholinesterase Overdose in Myasthenia Gravis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 g in 100 mL NS infused over 1530 min, followed by increments of 250 mg q5min prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give only if unable to give IV; <small>NOT</small> preferred routes.
         </li>
<li>Reconstitute as for direct IV injection (see below).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute 1-g vial by adding 20 mL NS to yield 50 mg/mL (a 5% solution). If pulmonary edema is present, give without
                  further dilution.  <span class="methodtype">IV Infusion:</span> Preferred method is to further dilute in 100 mL NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> In pulmonary edema, 1 g or fraction thereof over 5 min; do not exceed 200 mg/min.  <span class="methodtype">IV Infusion:</span> Give over 1530 min (preferred).  
               </p>
<ul>
<li>Stop infusion and reduce rate if hypertension occurs.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, headache, drowsiness. <span class="typehead">GI:</span> Nausea. <span class="typehead">Special Senses:</span> Blurred vision, diplopia, impaired accommodation. <span class="typehead">CV:</span> Tachycardia, hypertension (dose-related). <span class="typehead">Body as a Whole:</span> Hyperventilation, muscular weakness, <span class="speceff-life">laryngospasm</span>, muscle rigidity. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May potentiate the effects of <span class="classification">barbiturates</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 515 min IV; 1020 min IM. <span class="typehead">Distribution:</span> Distributed throughout extracellular fluids; crosses bloodbrain barrier slowly if at all. <span class="typehead">Metabolism:</span> Probably metabolized in liver. <span class="typehead"> Elimination:</span>  Rapidly excreted in urine. <span class="typehead">Half-Life:</span> 0.82.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP, vital signs, and I&amp;O. Report oliguria or changes in I&amp;O ratio.</li>
<li>Monitor closely. It is difficult to differentiate toxic effects of organophosphates or atropine from toxic effects of pralidoxime.</li>
<li>Be alert for and report immediately: Reduction in muscle strength, onset of muscle twitching, changes in respiratory pattern,
            altered level of consciousness, increases or changes in heart rate and rhythm.
         </li>
<li>Observe necessary safety precautions with unconscious patient because excitement and manic behavior reportedly may occur following
            recovery of consciousness.
         </li>
<li>Keep patient under close observation for 4872 h, particularly when poison was ingested, because of likelihood of continued
            absorption of organophosphate from lower bowel.
         </li>
<li>In patients with myasthenia gravis, overdosage with pralidoxime may convert cholinergic crisis into myasthenic crisis.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>